Find any stock by ticker or company name
All rights reserved.
442.17
0.00 (0.00%)
WATERTOWN, Mass.--(BUSINESS WIRE)--Treeline Biosciences, Inc. (“Treeline”) today announced a clinical trial collaboration and supply agreement with Roche (SIX: RO, ROP; OTCQX: RHHBY) to evaluate TLN-121, Treeline's BCL6 degrader, in combination with Roche's CD20xCD3 T-cell-engaging bispecific antibodies glofitamab and mosunetuzumab in separate combination cohorts for patients with B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL). Under the terms of the agreement, Treeline will.
Switzerland's Roche will pay $75 million upfront to Simcere Pharmaceutical Group for rights to an experimental blood cancer drug, the Chinese drugmaker said Tuesday.
FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.
The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma. Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to improving patient outcomes.
Jazz stock bounced off its buy zone Tuesday after the FDA approved its drug, Ziihera, to treat a form of stomach cancer.
The Food and Drug Administration has cleared a new blood test from Roche and Eli Lilly designed to help identify symptoms related to Alzheimer's disease in patients over age 55, Roche said on Monday morning.
The Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed by Roche and Eli Lilly.
There is no data to display
INDIANAPOLIS, Aug. 24, 2026 /PRNewswire/ -- Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has cleared the Elecsys® Phospho-Tau (217P) Plasma (pTau217) blood test, providing clinicians across primary and specialty care with a single blood-based option to aid in identifying amyloid pathology associated with Alzheimer's disease in individuals 55 years and older with signs, symptoms, or complaints of cognitive decline.4 Developed in collaboration with Eli Lilly and Company, Elecsys pTau217 is the first and only FDA-cleared, single-biomarker blood test that supports both rule-in and rule-out assessment of amyloid pathology using the same validated clinical cutoffs across primary and specialty care settings.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), today raised the final beam of its new manufacturing facility in Holly Springs, North Carolina, during a topping out ceremony – a construction milestone marking the completion of the manufacturing building's structural framework. The milestone reflects continued on-time progress on Genentech's approximately $2 billion investment in its first-ever East Coast manufacturing facility.
